Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Hum Exp Toxicol ; 33(1): 22-31, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23800999

RESUMEN

Philodryas baroni--an attractively colored snake--has become readily available through the exotic pet trade. Most people consider this species harmless; however, it has already caused human envenomation. As little is known about the venom from this South American opisthoglyphous "colubrid" snake, herein, we studied its protein composition by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), as well as its effects on the hemostatic system. Both reducing and nonreducing SDS-PAGE analysis demonstrated that the venom exhibits greatest complexity in the range of 50-80 kDa. The venom displayed proteolytic activity toward azocollagen, with a specific activity of 75.5 U mg⁻¹, and rapidly hydrolyzed the Aα-chain of fibrinogen, exhibiting lower activity toward the Bß- and γ-chains. The venom from P. baroni showed no platelet proaggregating activity per se, but it inhibited collagen- and thrombin-induced platelet aggregation. Prominent hemorrhage developed in mouse skin after intradermal injection of the crude venom, and its minimum hemorrhagic dose was 13.9 µg. When injected intramuscularly into the gastrocnemius of mice, the venom induced local effects such as hemorrhage, myonecrosis, edema, and leucocyte infiltration. Due to its venom toxicity shown herein, P. baroni should be considered dangerous to humans and any medically significant bite should be promptly reviewed by a qualified health professional.


Asunto(s)
Anticoagulantes/toxicidad , Colubridae , Endopeptidasas/toxicidad , Inhibidores de Agregación Plaquetaria/toxicidad , Proteínas de Reptiles/toxicidad , Venenos de Serpiente/toxicidad , Animales , Anticoagulantes/administración & dosificación , Anticoagulantes/química , Anticoagulantes/metabolismo , Argentina , Colágeno/metabolismo , Relación Dosis-Respuesta a Droga , Endopeptidasas/administración & dosificación , Endopeptidasas/química , Endopeptidasas/metabolismo , Fibrinógeno/metabolismo , Hemolíticos/administración & dosificación , Hemolíticos/química , Hemolíticos/metabolismo , Hemolíticos/toxicidad , Hemorragia/inducido químicamente , Humanos , Inyecciones Intradérmicas , Ratones , Ratones Endogámicos , Peso Molecular , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/patología , Necrosis , Inhibidores de Agregación Plaquetaria/administración & dosificación , Inhibidores de Agregación Plaquetaria/química , Inhibidores de Agregación Plaquetaria/metabolismo , Proteínas de Reptiles/administración & dosificación , Proteínas de Reptiles/química , Proteínas de Reptiles/metabolismo , Medición de Riesgo , Venenos de Serpiente/administración & dosificación , Venenos de Serpiente/química , Venenos de Serpiente/metabolismo , Especificidad por Sustrato
2.
Am J Trop Med Hyg ; 88(6): 1138-45, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23530079

RESUMEN

Anti-malarial 8-aminoquinolines drugs cause acute hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PDD). Efforts to develop non-hemolytic 8-aminoquinolines have been severely limited caused by the lack of a predictive in vivo animal model of hemolytic potential that would allow screening of candidate compounds. This report describes a G6PDD mouse model with a phenotype closely resembling the G6PDD phenotype found in the African A-type G6PDD human. These G6PDD mice, given different doses of primaquine, which used as a reference hemolytic drug, display a full array of hemolytic anemia parameters, consistently and reproducibly. The hemolytic and therapeutic indexes were generated for evaluation of hemotoxicity of drugs. This model demonstrated a complete hemolytic toxicity response to another known hemolytic antimalarial drug, pamaquine, but no response to non-hemolytic drugs, chloroquine and mefloquine. These results suggest that this model is suitable for evaluation of selected 8-AQ type candidate antimalarial drugs for their hemolytic potential.


Asunto(s)
Aminoquinolinas/efectos adversos , Anemia Hemolítica/fisiopatología , Antimaláricos/efectos adversos , Enfermedad Aguda , Aminoquinolinas/administración & dosificación , Anemia Hemolítica/etiología , Animales , Antimaláricos/administración & dosificación , Cloroquina/administración & dosificación , Cloroquina/efectos adversos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Genotipo , Deficiencia de Glucosafosfato Deshidrogenasa/genética , Deficiencia de Glucosafosfato Deshidrogenasa/metabolismo , Glutatión/sangre , Haptoglobinas/análisis , Hemolíticos/administración & dosificación , Hemolíticos/efectos adversos , Masculino , Mefloquina/administración & dosificación , Mefloquina/efectos adversos , Ratones , Fenotipo , Primaquina/administración & dosificación , Primaquina/efectos adversos , Recuento de Reticulocitos
3.
J Nanobiotechnology ; 9: 35, 2011 Sep 02.
Artículo en Inglés | MEDLINE | ID: mdl-21888630

RESUMEN

BACKGROUND: There is an urgent need to develop safe and effective adjuvants for the new generation of subunit vaccines. We developed the tubular immunostimulating complex (TI-complex) as a new nanoparticulate antigen delivery system. The morphology and composition of TI-complexes principally differ from the known vesicular immunostimulating complexes (ISCOMs). However, methodology for the preparation of TI-complexes has suffered a number of shortcomings. The aim of the present work was to obtain an antigen carrier consisting of triterpene glycosides from Cucumaria japonica, cholesterol, and monogalactosyldiacylglycerol from marine macrophytes with reproducible properties and high adjuvant activity. RESULTS: The cucumarioside A2-2 - cholesterol - MGalDG ratio of 6:2:4 (by weight) was found to provide the most effective formation of TI-complexes and the minimum hemolytic activity in vitro. Tubules of TI-complexes have an outer diameter of about 16 nm, an inner diameter of 6 nm, and a length of 500 nm. A significant dilution by the buffer gradually destroyed the tubular nanoparticles. The TI-complex was able to increase the immunogenicity of the protein antigens from Yersinia pseudotuberculosis by three to four times. CONCLUSIONS: We propose an optimized methodology for the preparation of homogeneous TI-complexes containing only tubular particles, which would achieve reproducible immunization results. We suggest that the elaborated TI-complexes apply as a universal delivery system for different subunit antigens within anti-infectious vaccines and enhance their economic efficacy and safety.


Asunto(s)
Galactolípidos/inmunología , ISCOMs/inmunología , Saponinas/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Animales , Antígenos Bacterianos/inmunología , Colesterol/inmunología , Glicósidos/inmunología , Hemolíticos/administración & dosificación , Humanos , Ratones , Nanopartículas/administración & dosificación , Triterpenos/inmunología , Yersinia pseudotuberculosis/inmunología
4.
Int J Hematol ; 93(5): 664-666, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21479984

RESUMEN

We report the occurrence of symptomatic methemoglobinemia in a previously healthy boy, who presented with severe acute hemolysis after fava bean ingestion. The methemoglobinemia revealed a previously unrecognized glucose-6-phosphate dehydrogenase (G6PD) deficiency. We discuss the pathophysiology of severe methemoglobinemia when associated with acute hemolysis, favism, and the common African G6PD A-variant [G6PD, VAL68MET, ASN126ASP]. In conclusion, screening for G6PD deficiency must be considered in symptomatic methemoglobinemia, especially in young boys, when associated with intravascular hemolysis.


Asunto(s)
Favismo/diagnóstico , Deficiencia de Glucosafosfato Deshidrogenasa/diagnóstico , Glucosafosfato Deshidrogenasa/sangre , Metahemoglobinemia/diagnóstico , Argelia , Niño , Ingestión de Alimentos , Favismo/complicaciones , Favismo/fisiopatología , Glucosafosfato Deshidrogenasa/genética , Deficiencia de Glucosafosfato Deshidrogenasa/complicaciones , Deficiencia de Glucosafosfato Deshidrogenasa/fisiopatología , Hemólisis/efectos de los fármacos , Hemolíticos/administración & dosificación , Hemolíticos/efectos adversos , Humanos , Masculino , Metahemoglobinemia/complicaciones , Metahemoglobinemia/fisiopatología , Mutación , Vicia faba/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...